# ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab

> **NCT05082259** · PHASE1 · RECRUITING · sponsor: **Institute of Cancer Research, United Kingdom** · enrollment: 61 (estimated)

## Conditions studied

- Advanced Cancer
- Cervical Cancer
- Triple Negative Breast Cancer

## Interventions

- **DRUG:** ASTX660
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05082259
- **Lead sponsor:** Institute of Cancer Research, United Kingdom
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-02
- **Primary completion:** 2026-03-16
- **Final completion:** 2026-03-16
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05082259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05082259, "ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05082259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*